The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan
This article was originally published in Pharmaceutical Approvals Monthly
Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.
You may also be interested in...
Year-end earnings reports from the biotech crowd show movement in the biosimilar field, faith in RNAi, high value for rare disease approaches and strategies to defend and grow primary assets.
Acorda plans to move Ampyra to Phase III for treating post-stroke deficits, after reporting positive Phase II results. The company also reported a signal from a small proof-of-concept study in cerebral palsy, but next steps are unclear in that indication.
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.